Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

October 16, 2020

Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

Exogenesis Corporation announced that it had acheived the primary endpoints of trapping and deactivating SARS-CoV-2 in simulated real-world exposures in a series of challenge tests for the Exogenesis Surgical Mask (ESM), a protective nose and mouth covering for healthcare workers and patients involved in medical and surgical procedures. Any innovation that enhances patient and clinician safety is welcome news to Yourway and our clients trying to conduct clinical trials during the pandemic.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Longwood Healthcare Leaders

October 27-28, 2025
Mandarin Oriental Hotel, Boston

Schedule a Meeting

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Schedule a Meeting

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat

Hello! How can I help you?